‘Preventing dementia will have a social and medical impact similar to 20th century vaccinations.’

Andrew McCaddon

Andrew McCaddon is a Principal General Practitioner in Wrexham, North Wales.

His work in the discovery of a mutation in the Amyloid Precursor Protein gene led to his key observation of low levels of vitamin B12 and folate in patients with Alzheimer’s disease.

In 1992 he described how such deficiencies contribute to impaired cognition and predicted that such patients would have elevated blood levels of homocysteine. This was confirmed by his research team in 1998. Elevated blood levels of homocysteine are now a recognised risk factor for dementia.

Dr McCaddon is also an Honorary Senior Research Fellow in the School of Medicine, Cardiff University. His MD with Distinction was awarded by Sheffield University for his thesis ‘Vitamin B12 deficiency and Alzheimer’s disease’ and he was awarded the 2010 William Farr Medal by the Worshipful Society of Apothecaries for his significant contribution to research concerning the care of elderly patients.

His description of how oxidative-stress causes B vitamin depletion forms the basis of Cobalz’s Platform Technology.

Andrew McCaddon

Andrew McCaddon

Address

Cobalz Limited
12A White Friars
Chester
CH1 1NZ
United Kingdom

Email

General information

Product information

Telephone

0844 9 400 400